Evidence map›Paper›PMID 41489510›Full record

ArticleCancer discovery2026

LINE-1 Locus Transcription Nucleates Oncogenic Chromatin Architecture.

Michael Lee, Yuannyu Zhang, Jun Yi Stanley Lim, Tao Dai, James Ye, Margaret B Cervantes, Varun Sondhi, Sisi Zheng, Yoon Jung Kim, Brandon Chen and 2 more

Abstract read
In one paragraph

Article in Cancer discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Evolution ofInternational journal of molecular sciences · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michael Lee *Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-3552-1872
Yuannyu Zhang *Center of Excellence for Leukemia Studies, Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-7016-7557
Jun Yi Stanley LimChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0003-4160-7434
Tao DaiChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0009-0009-9245-0378
James YeDepartment of Molecular Biology, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0001-5691-6649
Margaret B CervantesChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-2925-1896
Varun SondhiChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-0253-7624
Sisi ZhengDepartment of Pediatrics, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-0551-3863
Yoon Jung KimChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-2942-294X
Brandon ChenChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0009-0000-2784-5626
Ralph J DeBerardinisChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-2705-7432
Jian XuCenter of Excellence for Leukemia Studies, Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0003-1988-7337

Funding

Molecular Analysis of Transcriptional Enhancers in HematopoiesisR01DK111430 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Jian Xu · 2016 to 2026
$4.8M
Elucidating the Functional and Mechanistic Roles of LINE-1 Retrotransposons in Myeloid LeukemiaR01CA259581 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Jian Xu · 2022 to 2026
$2.3M
Targeting Metabolic Liabilities of Leukemia-Initiating Cells (R01CA230631)R01CA230631 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI XU, JIAN · 2019 to 2023
$1.8M
Dissecting the functional role of LINE1 retrotransposon-mediated interferon signaling in myeloid leukemiaF30CA275292 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI LEE, MICHAEL · 2022 to 2025
$179k
American Lebanese Syrian Associated Charities (ALSAC)Cancer Prevention and Research Institute of Texas (CPRIT) RP220337Cancer Prevention and Research Institute of Texas (CPRIT) RP220375Howard Hughes Medical Institute (HHMI)National Institutes of Health (NIH) F30CA275292National Institutes of Health (NIH) R01CA230631National Institutes of Health (NIH) R01CA259581National Institutes of Health (NIH) R01DK111430NCI NIH HHS R01 CA230631NCI NIH HHS R01 CA259581NIDDK NIH HHS R01 DK111430
6 · The paper itself

Abstract

Retrotransposons are genomic parasites frequently reactivated in cancers, in which their mobility can cause genetic alterations. However, it remains unclear whether their gene products contribute to cancer beyond mutagenesis. In this study, we uncover a chromatin-associated function of RNAs from long interspersed element-1 (LINE-1), the only autonomous retrotransposon in the human genome. Subcellular-resolved transcriptomics revealed that LINE-1 RNAs are primarily nascent transcripts produced by full-length, cell type-specific genomic copies of evolutionarily young subfamilies. Using a long-read chromosome conformation assay, we identified a class of highly interactive LINE-1 loci required for gene expression across cancer subtypes, revealing an unexpected regulatory role for LINE-1 locus transcription in oncogenic gene control. LINE-1 RNA depletion disrupted LINE-1-centric chromatin interactions and downregulated associated genes, whereas genomic insertion of an inducible LINE-1 generated de novo chromatin interactions in a transcription-dependent manner. Therefore, beyond their mutagenic potential, retrotransposons also regulate cancer gene expression by nucleating chromatin architecture through their transcriptional activity. SIGNIFICANCE: We developed a long-read chromatin conformation assay capable of resolving repetitive DNA, enabling the identification of highly interactive LINE-1 retrotransposon loci that nucleate chromatin architecture in cancer cells. This activity is driven by chromatin-associated LINE-1 transcripts, offering a biological rationale for the frequent reactivation of LINE-1 transcription in cancer.

Indexed as

ChromatinLong Interspersed Nucleotide ElementsNeoplasmsTranscription, GeneticCell Line, TumorGene Expression Regulation, NeoplasticHumansChromatin

Identifiers

PMID41489510
PMCPMC13040219

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.